Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AVGR | Avinger, Inc.

Index- P/E- EPS (ttm)-30.42 Insider Own0.20% Shs Outstand0.72M Perf Week197.84%
Market Cap9.90M Forward P/E- EPS next Y-8.70 Insider Trans-13.44% Shs Float0.67M Perf Month60.58%
Income-21.80M PEG- EPS next Q-2.85 Inst Own14.10% Short Float / Ratio0.62% / 0.00 Perf Quarter43.04%
Sales8.20M P/S1.21 EPS this Y4.60% Inst Trans- Short Interest0.00M Perf Half Y12.11%
Book/sh-0.72 P/B- EPS next Y56.10% ROA-97.30% Target Price24.00 Perf Year-29.82%
Cash/sh9.89 P/C1.39 EPS next 5Y- ROE- 52W Range4.14 - 24.30 Perf YTD-15.27%
Dividend- P/FCF- EPS past 5Y80.40% ROI-87.20% 52W High-43.25% Beta1.54
Dividend %- Quick Ratio0.40 Sales past 5Y-3.60% Gross Margin33.20% 52W Low233.49% ATR1.53
Employees67 Current Ratio0.60 Sales Q/Q-4.80% Oper. Margin- RSI (14)73.56 Volatility29.71% 15.86%
OptionableNo Debt/Eq- EPS Q/Q37.00% Profit Margin- Rel Volume19.11 Prev Close10.45
ShortableYes LT Debt/Eq- EarningsJul 27 AMC Payout- Avg Volume1.33M Price13.79
Recom2.00 SMA20100.38% SMA5049.96% SMA2009.88% Volume25,341,772 Change31.96%
Date Action Analyst Rating Change Price Target Change
Jun-29-21Initiated B. Riley Securities Buy $2.50
Mar-09-18Initiated Ladenburg Thalmann Buy
Apr-12-17Downgrade Oppenheimer Outperform → Perform
Apr-11-17Downgrade Canaccord Genuity Buy → Hold $4.30 → $1
Dec-29-15Downgrade Dougherty & Company Buy → Neutral
May-08-15Reiterated Dougherty & Company Buy $16 → $18
Apr-29-15Initiated Dougherty & Company Buy $16
Feb-24-15Initiated Oppenheimer Outperform $15
Feb-24-15Initiated Canaccord Genuity Buy $18
Sep-18-23 08:00AM
Aug-25-23 12:38PM
Aug-24-23 08:00AM
Aug-04-23 09:00AM
Jul-28-23 06:15AM
06:35PM Loading…
Jul-27-23 06:35PM
Jul-20-23 08:00AM
Jun-20-23 08:00AM
Jun-09-23 08:00AM
Jun-07-23 08:00AM
Jun-05-23 08:00AM
May-11-23 05:28AM
May-10-23 04:36PM
04:01PM Loading…
May-02-23 08:00AM
Apr-28-23 08:00AM
Apr-26-23 08:00AM
Mar-16-23 07:35AM
Mar-15-23 04:20PM
Mar-02-23 08:00AM
Jan-11-23 08:15AM
Nov-12-22 08:02AM
Nov-09-22 04:01PM
Nov-04-22 08:00AM
Nov-01-22 07:45AM
Oct-19-22 08:00AM
Sep-07-22 08:30AM
08:00AM Loading…
Sep-01-22 08:00AM
Aug-11-22 04:30PM
Aug-08-22 03:15PM
Aug-05-22 08:00AM
Aug-04-22 08:00AM
Jul-06-22 08:00AM
Jun-21-22 07:30AM
Jun-15-22 08:30AM
Jun-06-22 08:30AM
May-16-22 08:00AM
May-10-22 05:55PM
May-04-22 07:45PM
Apr-29-22 09:00AM
Apr-19-22 08:00AM
Mar-30-22 08:00AM
Mar-29-22 04:05PM
Mar-22-22 05:15PM
Mar-15-22 07:30AM
Mar-14-22 08:00AM
Mar-08-22 08:55AM
Mar-07-22 07:30AM
Mar-02-22 07:58AM
Feb-28-22 08:15AM
Feb-24-22 05:30PM
Feb-22-22 05:55PM
Jan-14-22 04:01PM
Jan-12-22 08:00AM
Jan-11-22 08:30AM
Nov-17-21 12:45PM
Nov-11-21 04:01PM
Nov-04-21 03:01PM
Oct-29-21 08:30AM
Oct-07-21 11:00AM
Sep-08-21 08:45AM
Sep-03-21 07:38AM
Aug-16-21 08:00AM
Aug-10-21 04:01PM
Aug-09-21 07:30AM
Jul-27-21 04:00PM
Jul-22-21 09:20AM
Jul-06-21 08:30AM
Jun-28-21 08:45AM
Jun-13-21 02:37PM
Jun-07-21 08:00AM
May-25-21 08:30AM
May-17-21 08:00AM
May-09-21 03:35AM
May-06-21 04:01PM
Apr-26-21 08:30AM
Apr-21-21 08:00AM
Apr-15-21 08:00AM
Apr-08-21 08:30AM
Mar-11-21 04:50PM
Mar-10-21 10:08AM
Mar-02-21 05:17PM
Feb-03-21 01:50PM
Feb-02-21 11:25AM
Jan-28-21 04:45PM
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Subainati Nabeel PaulVice President, FinanceMar 23Sale0.8122318185,672Mar 24 04:36 PM